EyePoint Pharmaceuticals, Inc. — Director's Dealing 2022

Jun 27, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: EyePoint Pharmaceuticals, Inc. (EYPT)
CIK: 0001314102
Period of Report: 2022-06-23

Reporting Person: ADAMIS ANTHONY P (N/A)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-06-23	Restricted Stock Units	$0.00	A	6000.00	Acquired		Common Stock (6000.00)	Direct
2022-06-23	Stock Option (Right to Buy)	$7.54	A	22000.00	Acquired	2032-06-23	Common Stock (22000.00)	Direct

Footnotes

F1: The restricted stock units will vest in three equal annual installments beginning June 23, 2023.

F2: The option becomes exercisable in three ratable annual installments beginning on June 23, 2023.